Diagnosis of gastrointestinal disorders
Status iFOBT is a rapid immunoassay for the qualitative detection of Immunochemical Fecal Occult Blood to detect human hemoglobin in human fecal specimens as an aid in the diagnosis of gastrointestinal disorders. It is a 30-test kit ideal for the physician's office to conduct routine patient screening. The patient's specimen sample can be collected in-office or at home with the inclusion of the user friendly instructions, sample collection tubes, and return mailing envelopes. Its superior sensitivity and specificity reduces the rate of false positive results often associated with traditional guaiac test methods. There are also no dietary or drug restrictions. With a quick and easy-to-perform test procedure, results are available in 5 to 10 minutes, and no other invasive methods are required.
Dual-Sample Test System
The Accutest® iFOBT Dual-Sample Test System is Jant Pharmacal Corporation's newest point-of-care product for colorectal cancer screening.
This immunological qualitative test detects human hemoglobin in feces and allows two samples to be tested-economically-on the same test device. Since polyps bleed intermittently,
testing more than one sample from different bowel movements improves accuracy and is recommended by the American Cancer Society. The Dual-Sample Test System is CLIA waived, easy to use,
requires no dietary restrictions and provides rapid results in less than five minutes. Convenient home collection materials include a unique buffer solution,
which allows 18-day stability of sample at room temperature. A single iFOBT test system is also available.
Reduce the number of false positive test results
Hemoccult ICT immunochemical fecal occult blood test -(iFOBT) can detect bleeding associated with more cancers and polyps than traditional guaiac-based FOBTs used for colorectal cancer screening.
It provides high specificity to reduce the number of false positive test results. It is non-invasive and very patient friendly, as there are no diet or drug restrictions for patients.
It provides 14-day on slide sample stability and is available in both two-day and three-day patient collection kits and in boxes of 100 individual collection cards.
Separate collection cards and test devices minimize the financial risk of patients not returning collection cards.
Beckman Coulter offers comprehensive patient educational support to accompany the Hemoccult ICT-helping to increase patient compliance.
Colorectal cancer screening
The CLIA-waived Hemosure® Immunochemical Fecal Occult
Blood Test (iFOBT) offers a notable consideration
in that there are no drug or diet restrictions.
It is a rapid, convenient, and
odorless test for the determination of human
hemoglobin in feces, typically used for
colorectal cancer screening. The one-step immunological fecal
occult blood test is a qualitative, sandwich dye conjugate immunoassay
and employs a unique combination of monoclonal and
polyclonal antibodies to selectively identify hemoglobin in test
samples with a high degree of sensitivity. In less than fi ve minutes,
elevated levels of human hemoglobin as low as 50 ng hHB/
mL can be detected and positive results for high levels of hemoglobin
can be seen in the test as early as one or two minutes.
